Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of JNJ-77242113 in ulcerative colitis
ISRCTN15936332Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial of icotrokinra in autoimmune colitis (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Ulcerative colitis disease evaluation and patient-reported outcomes. Started Oct 2023; status: completed.
02
Drugs
icotrokinra
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ISRCTN15936332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15936332.